2020
DOI: 10.1007/s13312-020-1893-8
|View full text |Cite
|
Sign up to set email alerts
|

Managing Children With Renal Diseases During the COVID-19 Pandemic

Abstract: The coronavirus outbreak is a rapidly evolving pandemic, placing unprecedented strain on health-care systems. COVID-19 presents challenges for management of children with renal diseases, especially those receiving long-term immunosuppressive medications, including renal transplant recipients and those with chronic kidney disease and acute kidney injury requiring dialysis. Our preparedness for managing this vulnerable group of children is the need of the hour. The purpose of this article is to provide guidance … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
27
0
3

Year Published

2020
2020
2021
2021

Publication Types

Select...
7

Relationship

2
5

Authors

Journals

citations
Cited by 16 publications
(30 citation statements)
references
References 12 publications
0
27
0
3
Order By: Relevance
“…In the presence of COVID-19-related moderate-severe respiratory symptoms, hospitalization and early identification of any signs of pneumonia are indicated. COVID-19-specific therapies should take into account underlying diseases (e.g., glomerular filtration in case of chronic renal failure), and the remodeling of immunosuppressive therapies should be considered on the basis of the severity of the infection and the type of drugs used [ 66 ]. If discontinued, immunosuppressive therapy should be resumed after two weeks in asymptomatic patients or after complete clinical resolution in symptomatic patients.…”
Section: Resultsmentioning
confidence: 99%
“…In the presence of COVID-19-related moderate-severe respiratory symptoms, hospitalization and early identification of any signs of pneumonia are indicated. COVID-19-specific therapies should take into account underlying diseases (e.g., glomerular filtration in case of chronic renal failure), and the remodeling of immunosuppressive therapies should be considered on the basis of the severity of the infection and the type of drugs used [ 66 ]. If discontinued, immunosuppressive therapy should be resumed after two weeks in asymptomatic patients or after complete clinical resolution in symptomatic patients.…”
Section: Resultsmentioning
confidence: 99%
“…consider increasing the interval between treatments if the risk of disease relapse is assessed to be low and/ or they have comorbidities that increase their risk of severe COVID-19 infection. 40,41,43,49 5. If immunosuppression is modified, clinics must have procedures in place to maintain close disease surveillance for early detection of relapse or progression, to minimize associated complications.…”
Section: For Children On Maintenance Rituximab Regimensmentioning
confidence: 99%
“…We suggest adhering to clinic visit schedules (virtual or in-person), where resources permit. 4,39-41…”
Section: Recommendations For Patients At Low-risk For Covid-19mentioning
confidence: 99%
See 2 more Smart Citations